glp-1 inhibitor drugs Medications: Everything You Need to Know Upcoming wave of hormone-based therapies

Glycemic monitoring with CGMs, glucose-lowering agents (GLP-1 receptor agonists), innovative insulin delivery systems, and mental health check-ins are just a few updates to the ADA 2025 Standards of Care.

People are losing 15, 20 percent of their body weight

2026: Acceleration and Market Transformation The coming year promises rapid evolution across innovation, policy, and market access

More and more evidence is showing that the use of DPP4 Inhibitors and GLP1 Receptor Agonists in combination, is a practice worth changing

Please consult your healthcare provider for personalized medical advice

In the subgroup analyses, human GLP-1 RAs, but not nonhuman GLP-1 RAs, reduced the risk of MACE in patients with HF (p interaction = 0.11)